Modulation of CLA, IL-12R, CD40L, and IL-2Rα expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275

Cellular Immunology

Volumn 247, Issue 1, 2007, Pages 1-11

  Reddy, Manjula ^a   Davis, Cuc ^a   Wong, Jackson ^a   Marsters, Paul ^a   Pendley, Charles ^a   Prabhakar, Uma ^a  

^a CENTOCOR INC   (United States)

Author keywords

CNTO 1275; Cytokines; IL 12; IL 17; IL 23; Psoriasis

Indexed keywords

CD40 LIGAND; CNTO 1275; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 23; LYMPHOCYTE ANTIGEN; MONOCLONAL ANTIBODY; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 23; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOPATHOGENESIS; LEUKOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PSORIASIS; TH1 CELL;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; CELL CULTURE TECHNIQUES; CYTOKINES; DOWN-REGULATION; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-12 RECEPTOR BETA 1 SUBUNIT; INTERLEUKIN-12 RECEPTOR BETA 2 SUBUNIT; INTERLEUKIN-12 SUBUNIT P40; INTERLEUKIN-17; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-23 SUBUNIT P19; INTERLEUKINS; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-12; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 34648836878     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2007.06.006     Document Type: Article

References (50)

1. Boyman O., Hefti H.P., Conrad C., Nickoloff B.J., Suter M., and Nestle F.O. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J. Exp. Med. 199 (2004) 731-736
2. Greaves M.W., and Weinstein G.D. Treatment of psoriasis. N. Engl. J. Med. 332 (1995) 581-588
3. Yawalkar N., Karlen S., Hunger R., Brand C.U., and Braathen L.R. Expression of interleukin-12 is increased in psoriatic skin. J. Invest. Dermatol. 111 (1998) 1053-1057
4. Lee E., Trepicchio W.L., Oestreicher J.L., Pittman D., Wang F., Chamian F., Dhodapkar M., and Krueger J.G. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199 (2004) 125-130
5. Piskin G., Sylva-Steenland R.M., Bos J.D., and Teunissen M.B. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J. Immunol. 176 (2006) 1908-1915
6. Ozenci V., Pashenkov M., Kouwenhoven M., Rinaldi L., Soderstrom M., and Link H. IL-12/IL-12R system in multiple sclerosis. J. Neuroimmunol. 114 (2001) 242-252
7. Yen D., Cheung J., Scheerens H., Poulet F., McClanahan T., McKenzie B., Kleinschek M.A., Owyang A., Mattson J., Blumenschein W., Murphy E., Sathe M., Cua D.J., Kastelein R.A., and Rennick D. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116 (2006) 1310-1316
8. Kikly K., Liu L., Na S., and Sedgwick J.D. The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr. Opin. Immunol. 18 (2006) 670-675
9. Parham C., Chirica M., Timans J., Vaisberg E., Travis M., Cheung J., Pflanz S., Zhang R., Singh K.P., Vega F., To W., Wagner J., O'Farrell A.M., McClanahan T., Zurawski S., Hannum C., Gorman D., Rennick D.M., Kastelein R.A., de Waal Malefyt R., and Moore K.W. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ-1 and a novel cytokine receptor subunit IL-23R. J. Immunol. 168 (2002) 5699-5708
10. Presky D.H., Yang H., Minetti L.J., Chua A.O., Nabavi N., Wu C.-Y., Gately M.K., and Gubler U. A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc. Natl. Acad. Sci. USA 93 (1996) 14002-14007
11. Vanden Eijnden S., Goriely S., De Wit D., Willems F., and Goldman M. IL-23 up-regulates IL-10 and induces IL-17 synthesis by polyclonally activated naive T cells in human. Eur. J. Immunol. 35 (2005) 469-475
12. Rosmarin D., and Strober B.E. The potential of interleukin 12 inhibition in the treatment of psoriasis. J. Drugs Dermatol. 4 (2005) 318-325
13. Sigmundsdottir H., Gudjonsson J.E., Jonsdottir I., Ludviksson B.R., and Valdimarsson H. The frequency of CLA+ CD8+ T cells in the blood of psoriasis patients correlates closely with the severity of their disease. Clin. Exp. Immunol. 126 (2001) 365-369
14. Sigmundsdottir H., Johnston A., Gudjonsson J.E., Bjarnason B., and Valdimarsson H. Methotrexate markedly reduces the expression of vascular E-selectin cutaneous lymphocyte-associated antigen and the numbers of mononuclear leucocytes in psoriatic skin. Exp. Dermatol. 13 (2004) 426-434
15. Clark R.A., Chong B., Mirchandani N., Brinster N.K., Yamanaka K., Dowgiert R.K., and Kupper T.S. The vast majority of CLA+ T cells are resident in normal skin. J. Immunol. 176 (2006) 4431-4439
16. Picker L.J., Terstappen L.W., Rott L.S., Streeter P.R., Stein H., and Butcher E.C. Differential expression of homing-associated adhesion molecules by T cell subsets in man. J. Immunol. 145 (1990) 3247-3255
17. Ferenczi K., Burak L., Pope M., Kruger J.G., and Austin L.M. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J. Autoimmun. 14 (2000) 63-78
18. Ohta Y., and Hamada Y. In situ expression of CD40 and CD40 ligand in psoriasis. Dermatology 209 (2004) 21-28
19. Flier J., Boorsma D.M., van Beek P.J., Nieboer C., Stoof T.J., Willemze R., and Tensen C.P. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J. Pathol. 194 (2001) 398-405
20. Rottman J.B., Smith T.L., Ganley K.G., Kikuchi T., and Krueger J.G. Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab. Invest. 81 (2001) 335-347
21. Shaker O.G., Moustafa W., Essmat S., Abdel-Halim M., and El-Komy M. The role of interleukin-12 in the pathogenesis of psoriasis. Clin. Biochem. 39 (2006) 119-125
22. Hong K., Chu A., Ludviksson B.R., Berg E.L., and Ehrhardt R.O. IL-12, independently of IFN-gamma plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J. Immunol. 162 (1999) 7480-7491
23. Reich K., Nestle F.O., Papp K., Ortonne J.-P., Evans R., Guzzo C., Li S., Dooley L.T., and Griffiths C.E. EXPRESS study investigators, Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366 (2005) 1367-1374
24. Chan J.R., Blumenschein W., Murphy E., Diveu C., Wiekowski M., Abbondanzo S., Lucian L., Geissler R., Brodie S., Kimball A.B., Gorman D.M., Smith K., de Waal Malefyt R., Kastelein R.A., McClanahan T.K., and Bowman E.P. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J. Exp. Med. 203 (2006) 2577-2587
25. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., McClanahan T., Kastelein R.A., and Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201 (2005) 233-240
26. Zheng Y., Danilenko D.M., Valdez P., Kasman I., Eastham-Anderson J., Wu J., and Ouyang W. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445 (2007) 648-651
27. Kauffman C.L., Aria N., Toichi E., McCormick T.S., Cooper K.D., Gottlieb A.B., Everitt D.E., Frederick B., Zhu Y., Graham M.A., Pendley C.E., and Mascelli M.A. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J. Invest. Dermatol. 123 (2004) 1037-1044
28. Krueger G.G., Langley R.G., Leonardi C., Yeilding N., Guzzo C., Wang Y., Dooley L.T., Lebwohl M., and CNTO 1275 Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of plaque psoriasis. N. Eng. J. Med. 356 (2007) 580-592
29. Alber G., Al-Robaiy S., Kleinschek M., Knauer J., Krumbholz P., Richter J., Schoeneberger S., Schuetze N., Schulz S., Toepfer K., Voigtlaender R., Lehmann J., and Mueller U. Induction of immunity and inflammation by interleukin-12 family members. Ernst Schering Res. Found. Workshop 56 (2006) 107-127
30. Leonard J.P., Waldburger K.E., and Goldman S.J. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J. Exp. Med. 181 (1995) 381-386
31. Matthys P., Vermeire K., Mitera T., Heremans H., Huang S., and Billiau A. Anti-IL-12 antibody prevents the development and progression of collagen-induced arthritis in IFN-gamma receptor-deficient mice. Eur. J. Immunol. 28 (1998) 2143-2151
32. Neurath M.F., Fuss I., Kelsall B.L., Stuber E., and Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182 (1995) 1281-1290
33. Watford W.T., Hissong B.D., Bream J.H., Kanno Y., Muul L., and O'Shea J.J. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol. Rev. 202 (2004) 139-156
34. Lowes M.A., Bowcock A.M., and Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 445 (2007) 866-873
35. Reddy M., Wong J., Davis C., and Prabhakar U. Co-expression of IL-12 receptors along with CXCR3 and CD25 on activated peripheral blood T lymphocytes. Cell. Immunol. 236 (2005) 123-130
36. Reddy M., Davis C., Wong J., and Prabhakar U. Cutaneous lymphocyte antigen expression on activated lymphocytes and its association with IL-12R (beta1 and beta2), IL-2R alpha, and CXCR3. Cell. Immunol. 236 (2005) 131-139
37. Hirohata S. Human Th1 responses driven by IL-12 are associated with enhanced expression of CD40 ligand. Clin. Exp. Immunol. 115 (1999) 78-85
38. Uyemura K., Yamamura M., Fivenson D.R., Modlin R.L., and Nickoloff B.J. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J. Invest. Dermatol. 101 (1993) 701-705
39. Arican O., Aral M., Sasmaz S., and Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17A, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 5 (2005) 273-279
40. Toichi E., Torres G., McCormick T.S., Chang T., Mascelli M.A., Kauffman C.L., Aria N., Gottlieb A.B., Everitt D.E., Frederick B., Pendley C.E., and Cooper K.D. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J. Immunol. 177 (2006) 4917-4926
41. Gottlieb A.B., Chamian F., Masud S., Cardinale I., Abello M.V., Lowes M.A., Chen F., Magliocco M., and Krueger J.G. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J. Immunol. 175 (2005) 2721-2729
42. Chamian F., Lowes M.A., Lin S.L., Lee E., Kikuchi T., Gilleaudeau P., Sullivan-Whalen M., Cardinale I., Khatcherian A., Novitskaya I., Wittkowski K.M., and Krueger J.G. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc. Natl. Acad. Sci. 102 (2005) 2075-2080
43. Weaver C.T., Hatton R.D., Mangan P.R., and Harrington L.E. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 25 (2007) 821-852
44. Happel K.I., Zheng M., Young E., Quinton L.J., Lockhart E., Ramsay A.J., Shellito J.E., Schurr J.R., Bagby G.J., Nelson S., and Kolls J.K. Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17A expression in response to Klebsiella pneumoniae infection. J. Immunol. 170 (2003) 4432-4436
45. McKenzie B.S., Kastelein R.A., and Cua D.J. Understanding the IL-23-IL-17 immune pathway. Trends Immunol. 27 (2006) 17-23
46. Hoeve M.A., Savage N.D.L., de Boer T., Langenberg D.M.L., de Waal Malefyt R., Ottenhoff T.H.M., and Verreck F.A. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. Eur. J. Immunol. 36 (2006) 661-670
47. Gerosa F., Paganin C., Peritt D., Paiola F., Scupoli M.T., Aste-Amezaga M., Frank I., and Trinchieri G. Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-gamma and interleukin-10. J. Exp. Med. 183 (1996) 2559-2569
48. Nickoloff B.J. Cracking the cytokine code in psoriasis. Nat. Med. 13 (2007) 242-244
49. Kastelein R.A., Hunter C.A., and Cua D.J. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 25 (2007) 221-242
50. Nestle F.O., and Conrad C. The IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasis. J. Invest. Dermatol. 123 (2004) xiv-xv